Updates in Management of SARS-CoV-2 Infection

Updates in Management of SARS-CoV-2 Infection

PNEUMONIA

INFECTIOUS DISEASES

Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus‑related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time‑consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS‑CoV‑2 infection.

Flisiak, Robert (editor)

https://directory.doabooks.org/handle/20.500.12854/93224

MDPI - Multidisciplinary Digital Publishing Institute

2022

Sulistiorini

https://creativecommons.org/licenses/by/4.0/

1. Robert Flisiak, Dorota Zarebska-Michaluk, Marta Flisiak-Jackiewicz and Piotr Rzymski
Updates in Management of SARS-CoV-2 Infection
2. Rodrigo San-Cristobal, Roberto Mart´ın-Hern´andez, Omar Ramos-Lopez, Diego
Martinez-Urbistondo, V´ıctor Mic´ o, Gonzalo Colmenarejo, Paula Villares Fernandez,
Lidia Daimiel and Jose Alfredo Mart´ınez
Longwise Cluster Analysis for the Prediction of COVID-19 Severity within 72 h of Admission:
COVID-DATA-SAVE-LIFES Cohort
3. Stefania Principe, Amelia Grosso, Alida Benfante, Federica Albicini, Salvatore Battaglia,
Erica Gini, Marta Amata, Ilaria Piccionello, Angelo Guido Corsico and Nicola Scichilone
Comparison between Suspected and Confirmed COVID-19 Respiratory Patients: What Is beyond the PCR Test
4. Jarosław Janc, Michał Sucha ´ nski, Magdalena Mierzchała-Pasierb, Ewa Wo´znica-Niesobska,
Lidia Łysenko and Patrycja Le´snik
Does the Serum Concentration of Angiotensin II Type 1 Receptor Have an Effect on the Severity
of COVID-19? A Prospective Preliminary Observational Study among Healthcare Professionals
5. Robert Flisiak, Piotr Rzymski, Dorota Zarebska-Michaluk, Magdalena Rogalska, Marta
Rorat, Piotr Czupryna, Beata Lorenc, Przemysław Ciechanowski, Dorota Kozielewicz, Anna
Piekarska, Maria Pokorska- ´ Spiewak, Katarzyna Sikorska, Magdalena Tudrujek, Beata
Bolewska, Grzegorz Angielski, Justyna Kowalska, Regina Podlasin, Włodzimierz Mazur,
Barbara Oczko-Grzesik, Izabela Zaleska, Aleksandra Szymczak, Paulina Fra ´ nczak-Chmura,
Małgorzata Sobolewska-Pilarczyk, Krzysztof Kłos, Magdalena Figlerowicz, Piotr
Leszczy ´ nski, Izabela Kucharek and Hubert Grabowski
Demographic and Clinical Overview of Hospitalized COVID-19 Patients during the First 17 Months of the Pandemic in Poland

Pdf

English

Textbooks

DOI
10.3390/books978-3-0365-5390-0